Patents Assigned to CLIO, INC.
  • Publication number: 20190307806
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 10, 2019
    Applicants: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Patent number: 10376544
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: August 13, 2019
    Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Patent number: 10369162
    Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: August 6, 2019
    Assignees: CLIO, INC., TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Mari Dezawa, Yoshinori Fujiyoshi, Masanori Yoshida
  • Patent number: 10293003
    Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: May 21, 2019
    Assignees: CLIO, INC., TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Mari Dezawa
  • Patent number: 10034889
    Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: July 31, 2018
    Assignees: CLIO, INC., TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Mari Dezawa, Yoshinori Fujiyoshi, Masanori Yoshida
  • Publication number: 20180050067
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Application
    Filed: November 3, 2017
    Publication date: February 22, 2018
    Applicants: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Patent number: 9844570
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: December 19, 2017
    Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Publication number: 20170304326
    Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 26, 2017
    Applicants: CLIO, INC., TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Mari Dezawa, YOSHINORI FUJIYOSHI, MASANORI YOSHIDA
  • Publication number: 20170128494
    Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.
    Type: Application
    Filed: January 23, 2017
    Publication date: May 11, 2017
    Applicants: CLIO, INC., TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Mari Dezawa, Teiji Tominaga
  • Publication number: 20170128498
    Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease.
    Type: Application
    Filed: January 23, 2017
    Publication date: May 11, 2017
    Applicants: CLIO, INC., TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Mari Dezawa
  • Patent number: 9446033
    Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: September 20, 2016
    Assignees: CLIO, INC., TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Mari Dezawa, Yoshinori Fujiyoshi, Masanori Yoshida